Pub Date : 2025-11-26DOI: 10.1136/bmjebm-2023-112485
Adrian Gheorghe, Abha Mehndiratta, Peter Baker, Sophie Gulliver, Malkeet Singh, Kirti Tyagi, Javier Guzman
{"title":"Measuring progress in institutionalising evidence-informed priority-setting in the Indian healthcare system: an application using the iProSE scale.","authors":"Adrian Gheorghe, Abha Mehndiratta, Peter Baker, Sophie Gulliver, Malkeet Singh, Kirti Tyagi, Javier Guzman","doi":"10.1136/bmjebm-2023-112485","DOIUrl":"10.1136/bmjebm-2023-112485","url":null,"abstract":"","PeriodicalId":9059,"journal":{"name":"BMJ Evidence-Based Medicine","volume":" ","pages":"s3-s7"},"PeriodicalIF":7.6,"publicationDate":"2025-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140064786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-26DOI: 10.1136/bmjebm-2023-112566
Malkeet Singh, Abha Mehndiratta, Manuel Antonio Espinoza, Shankar Prinja, Ursula Giedion
{"title":"Prioritisation of candidates for HTA: insights from the Indian healthcare landscape.","authors":"Malkeet Singh, Abha Mehndiratta, Manuel Antonio Espinoza, Shankar Prinja, Ursula Giedion","doi":"10.1136/bmjebm-2023-112566","DOIUrl":"10.1136/bmjebm-2023-112566","url":null,"abstract":"","PeriodicalId":9059,"journal":{"name":"BMJ Evidence-Based Medicine","volume":" ","pages":"s8-s10"},"PeriodicalIF":7.6,"publicationDate":"2025-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12355834/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143969812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-26DOI: 10.1136/bmjebm-2025-113740
Nicolás Meza, Paula Riganti, Kalipso Chalkidou
{"title":"Harnessing health technology assessment in India: paving the way for sustainable healthcare solutions in developing countries.","authors":"Nicolás Meza, Paula Riganti, Kalipso Chalkidou","doi":"10.1136/bmjebm-2025-113740","DOIUrl":"10.1136/bmjebm-2025-113740","url":null,"abstract":"","PeriodicalId":9059,"journal":{"name":"BMJ Evidence-Based Medicine","volume":" ","pages":"s1-s2"},"PeriodicalIF":7.6,"publicationDate":"2025-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143555860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-26DOI: 10.1136/bmjebm-2023-112490
Srobana Ghosh, C S Pramesh, Manju Sengar, Priya Ranganathan, Francis Ruiz, Tabassum Wadasadawala, Prakash Nayak, Jayashree Thorat, Apurva Ashok, Malkeet Singh, Abha Mehndiratta, Cassandra Nemzoff, Hiral Anil Shah
Background: Health technology assessment (HTA) is a valuable tool for informing the efficient allocation of resources in healthcare. However, the resource-intensive nature of HTA can limit its application, especially in low-resource settings. Adapting HTA processes by assessing the available international evidence offers a pragmatic approach to provide evidence for decision-making where resources are constrained.
Objective: This study piloted an adaptive HTA (aHTA) method to evaluate 10 cancer interventions.
Methods: We arranged a joint collaboration with the International Decision Support Initiative and the National Cancer Grid in India to form a working group of clinicians and health economists. We conducted a rapid review of HTA reports and economic evaluations for ten prioritised common cancer interventions for breast, lung, and head and neck cancers. We extracted data on cost-effectiveness, conducted a price benchmarking analysis, estimated treatment costs and calculated the treatment's share of the national insurance family allowance. Finally, we determined through qualitative appraisal whether the intervention would likely to be considered cost-effective in the Indian context.
Results: Of the 10 interventions assessed, 9 had sufficient evidence to make determinations on the likely cost-effectiveness. Three were potentially cost-effective (one after a price discount and another by using the generic price), while five were not, and one was only cost-effective in a subgroup. One intervention required a full HTA due to remaining uncertainty. Information on the likely cost-effectiveness, clinical and safety benefits, and treatment costs was consistently found through publicly available evidence. Assessment methods were modified slightly across the 10 interventions, including expanding the data extraction criteria, updating the calculations and broadening the evidence retrieval.
Conclusion: The aHTA method is a feasible resource-sensitive alternative to traditional HTA for informing decision-making in resource-constrained settings when ample international data on cost-effectiveness for a given topic is available.
{"title":"Exploring adaptive health technology assessment for evaluating 10 cancer interventions: insights and lessons from a pilot study in India.","authors":"Srobana Ghosh, C S Pramesh, Manju Sengar, Priya Ranganathan, Francis Ruiz, Tabassum Wadasadawala, Prakash Nayak, Jayashree Thorat, Apurva Ashok, Malkeet Singh, Abha Mehndiratta, Cassandra Nemzoff, Hiral Anil Shah","doi":"10.1136/bmjebm-2023-112490","DOIUrl":"10.1136/bmjebm-2023-112490","url":null,"abstract":"<p><strong>Background: </strong>Health technology assessment (HTA) is a valuable tool for informing the efficient allocation of resources in healthcare. However, the resource-intensive nature of HTA can limit its application, especially in low-resource settings. Adapting HTA processes by assessing the available international evidence offers a pragmatic approach to provide evidence for decision-making where resources are constrained.</p><p><strong>Objective: </strong>This study piloted an adaptive HTA (aHTA) method to evaluate 10 cancer interventions.</p><p><strong>Methods: </strong>We arranged a joint collaboration with the International Decision Support Initiative and the National Cancer Grid in India to form a working group of clinicians and health economists. We conducted a rapid review of HTA reports and economic evaluations for ten prioritised common cancer interventions for breast, lung, and head and neck cancers. We extracted data on cost-effectiveness, conducted a price benchmarking analysis, estimated treatment costs and calculated the treatment's share of the national insurance family allowance. Finally, we determined through qualitative appraisal whether the intervention would likely to be considered cost-effective in the Indian context.</p><p><strong>Results: </strong>Of the 10 interventions assessed, 9 had sufficient evidence to make determinations on the likely cost-effectiveness. Three were potentially cost-effective (one after a price discount and another by using the generic price), while five were not, and one was only cost-effective in a subgroup. One intervention required a full HTA due to remaining uncertainty. Information on the likely cost-effectiveness, clinical and safety benefits, and treatment costs was consistently found through publicly available evidence. Assessment methods were modified slightly across the 10 interventions, including expanding the data extraction criteria, updating the calculations and broadening the evidence retrieval.</p><p><strong>Conclusion: </strong>The aHTA method is a feasible resource-sensitive alternative to traditional HTA for informing decision-making in resource-constrained settings when ample international data on cost-effectiveness for a given topic is available.</p>","PeriodicalId":9059,"journal":{"name":"BMJ Evidence-Based Medicine","volume":" ","pages":"s20-s28"},"PeriodicalIF":7.6,"publicationDate":"2025-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12213987/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142920467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-26DOI: 10.1136/bmjebm-2023-112487
Pankaj Bahuguna, Peter Alan Baker, Andrew Briggs, Sophie Gulliver, Hannah Hesselgreaves, Abha Mehndiratta, Francis Ruiz, Kirti Tyagi, Olivia Wu, Javier Guzman, Eleanor Grieve
An increasing investment in health technology assessment (HTA) in low-income and middle-income countries has generated greater interest from policy-makers about the value and return on investment (ROI) of HTA. Few studies have, however, quantified the benefits of HTA in terms of its value to the health system. This evaluation aims to quantify the impact and ROI achieved by the HTA agency in India (HTAIn).A framework developed by the University of Glasgow was used to review three 'hta's commissioned by HTAIn between 2018 and 2020, taking into account the opportunity cost of investing in these processes. Costs included fixed costs for HTAIn and costs for undertaking each 'hta'. Attributable benefits are calculated by subtracting the counterfactual (benefits that might have been realised without an HTA) from realised benefits.HTAIn sits under the Department of Health Research, Ministry of Health and Family Welfare, Government of India. It was set up to facilitate the process of transparent and evidence-informed decision-making in healthcare in India.HTA helps decision-makers to understand the consequences of alternative courses of action and to select the options that produce the best outcomes at the lowest cost. Institutionalisation of HTA is seen as pivotal to supporting universal health coverage as a means of supporting a better allocation of finite resources, cost containment and the maximisation of health.Net health benefits are our measure of value. The ROI of HTAIn is calculated by aggregating attributable benefits and offsetting them against the costs of investment.Our findings show that investing in HTAIn yields a return of 9:1, with potential to increase to 71:1 with full implementation of HTA recommendations. Variability of ROI ranged from 5:1 to 40:1 between the different interventions and diseases.While HTAIn requires financial investment, it is an efficient use of resources. The potential for greater impact and the variability of the ROI between interventions underline the importance of planning for implementation and good topic selection in HTA.
{"title":"Is health technology assessment value for money? Estimating the return on investment of health technology assessment in India (HTAIn).","authors":"Pankaj Bahuguna, Peter Alan Baker, Andrew Briggs, Sophie Gulliver, Hannah Hesselgreaves, Abha Mehndiratta, Francis Ruiz, Kirti Tyagi, Olivia Wu, Javier Guzman, Eleanor Grieve","doi":"10.1136/bmjebm-2023-112487","DOIUrl":"10.1136/bmjebm-2023-112487","url":null,"abstract":"<p><p>An increasing investment in health technology assessment (HTA) in low-income and middle-income countries has generated greater interest from policy-makers about the value and return on investment (ROI) of HTA. Few studies have, however, quantified the benefits of HTA in terms of its value to the health system. This evaluation aims to quantify the impact and ROI achieved by the HTA agency in India (HTAIn).A framework developed by the University of Glasgow was used to review three 'hta's commissioned by HTAIn between 2018 and 2020, taking into account the opportunity cost of investing in these processes. Costs included fixed costs for HTAIn and costs for undertaking each 'hta'. Attributable benefits are calculated by subtracting the counterfactual (benefits that might have been realised without an HTA) from realised benefits.HTAIn sits under the Department of Health Research, Ministry of Health and Family Welfare, Government of India. It was set up to facilitate the process of transparent and evidence-informed decision-making in healthcare in India.HTA helps decision-makers to understand the consequences of alternative courses of action and to select the options that produce the best outcomes at the lowest cost. Institutionalisation of HTA is seen as pivotal to supporting universal health coverage as a means of supporting a better allocation of finite resources, cost containment and the maximisation of health.Net health benefits are our measure of value. The ROI of HTAIn is calculated by aggregating attributable benefits and offsetting them against the costs of investment.Our findings show that investing in HTAIn yields a return of 9:1, with potential to increase to 71:1 with full implementation of HTA recommendations. Variability of ROI ranged from 5:1 to 40:1 between the different interventions and diseases.While HTAIn requires financial investment, it is an efficient use of resources. The potential for greater impact and the variability of the ROI between interventions underline the importance of planning for implementation and good topic selection in HTA.</p>","PeriodicalId":9059,"journal":{"name":"BMJ Evidence-Based Medicine","volume":" ","pages":"s29-s37"},"PeriodicalIF":7.6,"publicationDate":"2025-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143668657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-26DOI: 10.1136/bmjebm-2023-112491
Adrian Gheorghe, Abha Mehndiratta, Peter Baker, Anthony Culyer, Shankar Prinja, Sitanshu Sekhar Kar, Javier Guzman
{"title":"Health technology assessment in India in the next decade: reflections on a vision for its path to maturity and impact.","authors":"Adrian Gheorghe, Abha Mehndiratta, Peter Baker, Anthony Culyer, Shankar Prinja, Sitanshu Sekhar Kar, Javier Guzman","doi":"10.1136/bmjebm-2023-112491","DOIUrl":"10.1136/bmjebm-2023-112491","url":null,"abstract":"","PeriodicalId":9059,"journal":{"name":"BMJ Evidence-Based Medicine","volume":" ","pages":"s38-s40"},"PeriodicalIF":7.6,"publicationDate":"2025-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139641591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-26DOI: 10.1136/bmjebm-2023-112484
Victoria Y Fan, Abha Mehndiratta, Jubilee Ahazie
{"title":"Making an organisation for health technology assessment: lessons from India.","authors":"Victoria Y Fan, Abha Mehndiratta, Jubilee Ahazie","doi":"10.1136/bmjebm-2023-112484","DOIUrl":"10.1136/bmjebm-2023-112484","url":null,"abstract":"","PeriodicalId":9059,"journal":{"name":"BMJ Evidence-Based Medicine","volume":" ","pages":"s41-s42"},"PeriodicalIF":7.6,"publicationDate":"2025-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140130615","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-20DOI: 10.1136/bmjebm-2025-113904
Claudia Cecconi Ebm, Alina Herrmann, Antonio Bognanni, Mehdi Aloosh, Charlotte Michels, Rafael Vieira, Grigorios Leontiadis, Thomas Piggott, Holger J Schuenemann
{"title":"A primer to planetary health in evidence-based medicine and clinical decision-making.","authors":"Claudia Cecconi Ebm, Alina Herrmann, Antonio Bognanni, Mehdi Aloosh, Charlotte Michels, Rafael Vieira, Grigorios Leontiadis, Thomas Piggott, Holger J Schuenemann","doi":"10.1136/bmjebm-2025-113904","DOIUrl":"https://doi.org/10.1136/bmjebm-2025-113904","url":null,"abstract":"","PeriodicalId":9059,"journal":{"name":"BMJ Evidence-Based Medicine","volume":" ","pages":""},"PeriodicalIF":7.6,"publicationDate":"2025-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145562875","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-29DOI: 10.1136/bmjebm-2025-114276
Antonio Alcántara Montero
{"title":"Reconsidering the role of tramadol in chronic pain management.","authors":"Antonio Alcántara Montero","doi":"10.1136/bmjebm-2025-114276","DOIUrl":"https://doi.org/10.1136/bmjebm-2025-114276","url":null,"abstract":"","PeriodicalId":9059,"journal":{"name":"BMJ Evidence-Based Medicine","volume":" ","pages":""},"PeriodicalIF":7.6,"publicationDate":"2025-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145399836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}